Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
about
Mechanisms of hypoglycemia unawareness and implications in diabetic patients55P0110, a Novel Synthetic Compound Developed from a Plant Derived Backbone Structure, Shows Promising Anti-Hyperglycaemic Activity in MiceThe investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratPharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study.Severe hypoglycemia from clarithromycin-repaglinide drug interaction.New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.Hypoglycemia revisited in the acute care setting.Use of Metformin in Patients with Kidney and Cardiovascular Diseases.Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetesDeath during intensive glycemic therapy of diabetes: mechanisms and implications.The importance of hypoglycemia in diabetic patients.Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemicsTreatment of hypertension and diabetes mellitus in patients with chronic kidney disease: a review.Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach.Management of type 2 diabetes mellitus in older patients: current and emerging treatment options.Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Optimal utilisation of sulphonylureas in resource-constrained settingsInsulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.Severe hypoglycemia is a serious complication and becoming an economic burden in diabetesCharacterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells.Hypoglycemia in type 2 diabetes: Standpoint of an experts' committee (India hypoglycemia study group).Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.Role and prevalence of impaired awareness of hypoglycaemia in ambulance service attendances to people who have had a severe hypoglycaemic emergency: a mixed-methods study.Hypoglycaemia in diabetes: do we think enough of the cause? An observational study on prevalence and causes of hypoglycaemia among patients with type 2 diabetes in an out-patient setting in Sri Lanka.
P2860
Q26799608-330DE05C-398F-4FBC-946B-F813433CA2E2Q28547237-69716ED2-8B87-4C5E-85AF-09751E032504Q33442343-AC45FC1F-7540-4D27-A772-ACD378500E6EQ33555327-F40ACD0A-2F6B-41D9-B7AF-084A29BDB0DEQ33993320-E684924C-4F53-4255-9E4E-5C3D4E5B5477Q34329486-E9A82351-73FF-4024-9F60-7877D15E5447Q34591309-BFBA1E4A-0416-4E95-A4EA-0FA790F0D868Q35153309-31488366-34C4-42CA-BF5E-32A022739A42Q35561860-E6506378-7DCE-4F62-BB06-9F1C7224E3A5Q35688570-15642998-E151-480A-BFE6-9BD2B4C471F0Q36088468-F92F4E5B-3FE3-48B7-AF47-51CF5E704E36Q36297059-667BB186-D905-42D5-A406-ED95D52FDFB1Q36686257-37C3FFE2-99D4-4758-9C41-2698E7B6CCE3Q36945255-5FD0191C-FAC6-47E8-BB52-585F3A6A1809Q36959603-4BDE205F-E5A8-4EEE-900C-CA3EC3A2338BQ36968170-64AD3F36-C5DD-478F-8950-AA7522754758Q37405143-AF8CA661-81D4-439A-AD0B-46B57429B1E6Q37468429-26428AD5-E552-49D3-8A2F-672CEAF798CBQ37890773-DE339142-B4B4-472E-A882-BAB614F09348Q38059889-45951E66-BDD5-4BFB-93B8-00079A101374Q38168993-88535231-3234-4E2F-A9B7-41AABF71677EQ38213126-2742AB7D-9FCB-4A5F-9A65-F47D0C606650Q38241834-4A396F72-690B-4B19-B02B-A8A47AD8F468Q40963671-20E8F688-0CC6-4969-975E-51B55D172BF8Q41477500-6E93BACD-59D0-4949-9C60-AC0FFAF72289Q41768498-EDE7AAC2-5050-4DD3-8AB7-E00ABC9B5D4BQ42274527-C8B4B12B-28BA-4E11-B23E-1E844F8031FEQ42283206-FA45C580-9063-479B-A666-C6DD0C8993A1Q42758783-0F8E5601-213D-4C7C-83B1-336985CCE143Q43248039-6CA1E254-FB67-436F-B12E-74E539E27C94Q44676456-7110F1CB-4474-4802-8EEC-69B1289EDA2CQ50263760-B6E31B5B-F582-467A-B1F9-AF4BD80B094DQ55000319-F08007AB-A5CE-4D96-A823-9A3EC47BD360Q55476876-74832C28-42C6-47B3-A0FF-48289B5D8611
P2860
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@ast
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@en
type
label
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@ast
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@en
prefLabel
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@ast
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@en
P356
P1476
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
@en
P2093
Egberts EH
Holstein A
P304
P356
10.1055/S-2003-44287
P577
2003-10-01T00:00:00Z